Clinical trials: Lymphoma
B-cell Non Hodgkin Lymphoma, Advanced Solid Tumor
Study of PCLX-001 in R/R Advanced Solid Malignancies and B-cell Lymphoma
This is a phase I dose-escalation study of oral PCLX-001, conducted in a multicenter, non-randomized, open-label, non-controlled design.
- Trial name
- NCT04836195
- Testing
- PCLX-001 - 20mg, PCLX-001 - 40mg, PCLX-001 - 70mg
- Where
- 4 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Pacylex Pharmaceuticals
Mantle Cell Lymphoma
Rituximab/Bendamustine + Rituximab/Cytarabine for Mantle Cell Lymphoma
Mantle cell lymphoma (MCL) is not curable with conventional therapy. This study sought to improve upon standard of care in newly diagnosed, untreated MCL patients who were transplant-eligible using drugs already established as…
- Trial name
- NCT01661881
- Testing
- Rituximab, Bendamustine, Cytarabine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Christine Ryan
Lymphoma, Non-Hodgkin, MALT Lymphoma
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
The purpose of this study is to determine the effectiveness of six cycles of concurrent fludarabine and rituximab in patients with mucosa-associated lymphoid tissue (MALT) lymphoma, marginal zone lymphoma (MZL) or CD5-, CD10…
- Trial name
- NCT00117156
- Testing
- Fludarabine, Rituximab
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Follicular
A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin's Lymphoma
Patients will receive a standard 5 mCi dosimetric dose of fission-derived Iodine I 131 Tositumomab. Pharmacokinetic data for the primary endpoint analysis will be derived from testing done on blood samples drawn at 12 timepoints…
- Trial name
- NCT00315731
- Testing
- Follicular Lymphoma
- Volunteers
- 15 people
- Sponsor
- GlaxoSmithKline
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma
Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma
This phase II trial studies how well rituximab and pembrolizumab with or without lenalidomide works in treating patients with follicular lymphoma and diffuse large B-cell lymphoma that has returned after a period of improvement.
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma
- Trial name
- NCT02446457
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Pembrolizumab
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Allogeneic Hematopoietic Cell Transplantation for Patients With Busulfex-based Regimen
RATIONALE: Giving chemotherapy, such as fludarabine and busulfan, before a donor peripheral stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- LCCC0510 (NCT00448357)
- Testing
- rabbit anti-thymocyte globulin (ATG), therapeutic allogeneic lymphocytes, busulfan
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma
This study will determine the overall response rate and toxicity of rituximab and Velcade in combination in patients with relapsed or refractory mantle cell non-Hodgkin's lymphoma.
- Trial name
- NCT00201877
- Testing
- Velcade, Rituximab
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Mantle Cell Lymphoma
Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma
This phase I/II trial studies the side effects and best dose of bortezomib when given with rituximab and chemotherapy drugs and to see how well they work in treating participants with mantle cell lymphoma.
- Trial name
- NCT00477412
- Testing
- Bortezomib, Cyclophosphamide, Cytarabine
- Where
- United States
- Volunteers
- 107 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Follicular Lymphoma
An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular Lymphoma
This open-label, single arm study will evaluate the safety of obinutuzumab administered as a short duration infusion (SDI; target 90-minute infusion) during cycle 2 and from cycle 2 onwards in combination with chemotherapy in…
- Trial name
- NCT03817853
- Testing
- Obinutuzumab, Bendamustine, Cyclophosphamide
- Where
- 33 sites in United States, Brazil and 5 more
- Volunteers
- 114 people
- Sponsor
- Hoffmann-La Roche
Primary Effusion Lymphoma, B-Cell Neoplasm
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma
Background: Primary effusion lymphoma (PEL) is a rare disease with no standard treatment. Researchers want to see if a drug called lenalidomide along with common chemotherapy drugs may be effective in treating PEL.
- Trial name
- NCT02911142
- Testing
- Lenalidomide, Rituximab, Prednisone
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Moderate or Severe Submental Fullness
Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area
To evaluate the safety and efficacy of deoxycholic acid injection in the reduction of submental fat (fat below the chin).
- Trial name
- NCT01546142
- Testing
- Deoxycholic acid injection
- Where
- 35 sites in United States, Canada
- Volunteers
- 516 people, healthy volunteers welcome
- Sponsor
- Kythera Biopharmaceuticals
Multiple Myeloma, Lymphoma
Ixazomib Rollover Study
The purpose of this study is to provide continued access to ixazomib and/or other study drugs from an ixazomib parent study.
- Conditions
- Multiple Myeloma, Lymphoma, Amyloidosis
- Trial name
- NCT02924272
- Testing
- Ixazomib
- Where
- 26 sites in United States, Belgium and 9 more
- Volunteers
- 32 people
- Sponsor
- Takeda
Leukemia, Lymphoma, Non-Hodgkin
Phase 2 Study of Atorvastatin Safety and Antitumor Effects in Non-Hodgkin's Lymphoma
This is an approach which can inflict significant toxicity. An alternative is to block expression of oncogenes which are over-expressed only in cancer cells, a therapeutic approach which could reduce toxicity to the host while…
- Trial name
- NCT00185731
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Dean Felsher
Extracorporeal Membrane Oxygenation Complication, Pediatric ALL
Study Comparing Bivalirudin Versus Heparin in Neonatal and Pediatric ECMO
The investigators will prospectively enroll 30 neonatal and pediatric ECMO patients at a single pediatric Level 1 trauma center.
- Conditions
- Extracorporeal Membrane Oxygenation Complication, Pediatric ALL, Anticoagulants
- Trial name
- NCT03318393
- Testing
- Bivalirudin, Unfractionated heparin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Texas Southwestern Medical Center
Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma
Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
This phase I/II trial studies the best dose and side effects of mogamulizumab in combination with pembrolizumab and to see how well they work in treating patients with diffuse large B cell lymphoma that have come back after a…
- Conditions
- Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma
- Trial name
- NCT03309878
- Testing
- Mogamulizumab, Pembrolizumab
- Where
- 8 sites in United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
B-Cell Lymphoma Originating in the CNS
The Addition of Temozolomide to Conditioning for Autologous Transplantation in Relapsed & Refractory CNS Lymphoma
The primary purpose of the study will be testing the dosing of temozolomide to find the target dose that a person can tolerate. The other part of the study will be determining how helpful it can be to CNS lymphoma patients by…
- Trial name
- DRBEAT (NCT01235793)
- Testing
- Temozolomide
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Cedars-Sinai Medical Center
Diffuse Large B-Cell Lymphoma
Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
This randomized, placebo-controlled phase 3 study planned to enroll approximately 235 treatment-naïve subjects with high-risk Diffuse Large B-Cell Lymphoma (DLBCL).
- Trial name
- NCT03263026
- Testing
- Enzastaurin Hydrochloride
- Where
- 39 sites in United States, China
- Volunteers
- 256 people
- Sponsor
- Denovo Biopharma LLC
Hematological Malignancies
Trial Of Double Umbilical Cord Blood Transplantation
This pilot research study is to investigate the safety and effectiveness of stem cell transplantation to treat blood-related (hematopoietic) cancers, using stem cells collected from two different, umbilical cord blood donors.
- Trial name
- NCT00763490
- Testing
- Full intensity, double umbilical cord, stem cell transplant, Flu/Bu4 conditioning regimen, Total Lymphoid Irradiation (TLI)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Michigan Rogel Cancer Center
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia
High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia
This pilot clinical trial studies the feasibility of choosing treatment based on a high throughput ex vivo drug sensitivity assay in combination with mutation analysis for patients with acute leukemia that has returned after a…
- Conditions
- Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT02551718
- Testing
- Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Washington
Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
This is a two-cohort, multicenter, open-label study of tafasitamab (MOR208) combined with idelalisib or venetoclax in adult patients with R/R CLL or R/R SLL pretreated with a BTK inhibitor (e.g., ibrutinib) as single agent or as…
- Conditions
- Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- COSMOS (NCT02639910)
- Testing
- Tafasitamab, Idelalisib, Venetoclax
- Where
- 17 sites in United States, Austria and 4 more
- Volunteers
- 24 people
- Sponsor
- MorphoSys AG
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.